Treatment of nitric oxide inhalation in pulmonary hypertension
一氧化氮吸入在肺动脉高压中的治疗

摘要

目的 分析一氧化氮吸入在肺动脉高压中的治疗价值。方法 选取2022年1月-2023年1月我院收治的82例肺动脉高压患者作为实验样本，依据治疗方法差异，分为对照组和治疗组，分别予以常规机械通气治疗、机械通气联合一氧化氮吸入治疗，就两组的临床疗效及其炎症介质相关指标的变化。结果 治疗组和对照组在临床疗效上数值对比差异明显，分别为97.56%（40/41）和68.29%（28/41），有统计学意义（P<0.05）。治疗组和对照组在治疗1周后，HMGB1（高迁移率族蛋白）平均灰度值与RAGE（糖基化终末产物受体）水平比较上差异显著，有统计学意义（P<0.05）。结论 一氧化氮吸入在肺动脉高压中的治疗效果突出，疗效和安全性极高，值得大力推广。

Abstract

Objective To analyze the therapeutic value of nitric oxide inhalation in pulmonary hypertension.
Methods A total of 82 patients with pulmonary hypertension admitted to our hospital from January 2022 to January 2023 were selected as experimental samples. According to the differences in treatment methods, they were divided into control group and treatment group, which were given routine mechanical ventilation therapy or mechanical ventilation combined with nitric oxide inhalation therapy, respectively. The clinical efficacy and changes of inflammatory mediators related indexes of the two groups were analyzed.
Results There were significant differences in clinical efficacy between the treatment group and the control group, 97.56% (40/41) and 68.29% (28/41), respectively, with statistical significance (P<0.05). After 1 week of treatment, the average gray value of HMGB1 (high mobility group protein) and RAGE (glycosylated end-product receptor) levels were significantly different between the treatment group and the control group (P<0.05).
Conclusion   Nitric oxide inhalation is effective and safe in the treatment of pulmonary hypertension, which is worth promoting.